Bullous Diseases

WEDNESDAY, Aug. 2, 2023 &nbsp;-- For patients with bullous pemphigoid (BP), dupilumab is associated with improved clinical symptoms, according to a study published online Aug. 2 in JAMA Dermatology.Liuqi Zhao, M.D., from Peking University First Hospital in China, and colleagues examined the efficacy and safety of dupilumab in patients with BP in a retrospective cohort study. A total of 146 adult patients with a clinical presentation of BP combined with immunological or pathological evidence, who received 300 mg of dupilumab every two weeks following an initial dose of 600 mg, were included in the study.The researchers found that 87.0 percent of the patients achieved disease control within four weeks (median time, 14 days). Overall, 35.6 and 8.9 percent of patients achieved complete remission and relapsed during the observation period, respectively. At week 64, the complete remission rate and cumulative relapse rate were 62.5 and 30.9 percent, respectively. After dupilumab treatment, rapid and sustained improvement in clinical indicators and laboratory examination results were seen, including Bullous Pemphigoid Disease Area Index scores, itching numerical rating scale scores, serum anti-BP180 and anti-BP230 antibodies, total immunoglobulin E levels, and eosinophil count. Overall, 73.3 percent of the patients did not report any adverse events. Infections and eosinophilia were the most common adverse events. Serum anti-BP180 antibody levels &gt;50 relative units/mL were associated with four-week disease control (odds ratio, 3.63; 95 percent confidence level, 0.97 to 12.61; P = 0.045), while relapse was more likely among male patients (hazard ratio, 10.97; 95 percent confidence level, 1.42 to 84.92; P = 0.02)."We found that dupilumab effectively alleviated clinical and serological indicators of patients with BP," the authors write. "The safety profile was favorable, while the risk of infection and eosinophilia were notable concerns."

Rapid and sustained improvement in clinical indicators and laboratory examination results seen after treatment

 Do Clinical Symptoms Improve With Dupilumab in Bullous Pemphigoid?

In episode 25 of Cutaneous Miscellaneous, our host, Nicholas Brownstone, MD, chats with Charlie Dunn, MD, board-certified pediatrician and Chief Dermatology Resident at KCU-GME Consortium / ADCS Orlando Dermatology Residency Program in Orlando, FL.&nbsp;

In episode 25 of Cutaneous Miscellaneous, our host, Nicholas Brownstone, MD, chats with Charlie Dunn, MD, board-certified pediatrician and Chief Dermatology Resident at KCU-GME Consortium / ADCS Orlando Dermatology Residency Program in Orlando, FL.&nbsp;The episode begins with board review on epidermolysis bullosa (EB). Dr Brownstone briefly highlights board review pearls on transport media used in dermatopathology. Next, Dr Dunn and Dr Brownstone discuss high-yield board review facts on the genetics, onset, diagnosis, morphology, associated clinical features, and prognosis of all the major subtypes of EB simplex, junctional EB and dystrophic EB. &nbsp;Dr Dunn and Dr Brownstone then discuss everything Camp Discovery. Dr Brownstone asks Dr Dunn about the history of Camp Discovery and which types of patients are eligible. Dr Dunn discusses a typical day at Camp Discovery including which activities are available and the kinds of counselors who staff the camp. Finally, Dr Dunn provides detailed information on how to refer a pediatric patient to the camp, which is completely free for the camper and their family! &nbsp;Year after year, there are open spots at Camp Discovery. Listen now to learn about this amazing experience for your pediatric patients with skin disease and how you can make a referral!More InformationGeneral information on <a target="_blank" rel="noopener noreferrer" href="https://www.aad.org/public/public-health/camp-discovery">Camp Discovery</a> from the AADApply to be a <a target="_blank" rel="noopener noreferrer" href="https://www.aad.org/public/public-health/camp-discovery/volunteer">Camp Discovery Volunteer</a>Access the <a target="_blank" rel="noopener noreferrer" href="https://www.aad.org/public/public-health/camp-discovery/referrals">Camp Discovery Patient Referral Form</a>For questions or more detailed information, please contact Janine Mueller at <a href="mailto:jmueller@aad.org" target="_blank" rel="noopener noreferrer">jmueller@aad.org</a> or call (847) 240-1737.&nbsp;Cutaneous Miscellaneous Boards Booster!In this new feature, we’ll put your knowledge to the test with high-yield board review questions written by dermatology residents and fellows and sourced from key resources like Bolognia’s Dermatology, Andrews’ Dermatology, and Alikhan’s Review of Dermatology. These quiz questions will test your skills on the board review topic that’s discussed in each episode. <a target="_blank" rel="noopener noreferrer" href="https://www.research.net/r/FGZ6JV7?Email=[Email_value]">Click here to begin.</a>

Bullous Diseases Condition Center

Featured in Bullous Diseases

Bullous Diseases Episodes to Explore

Discovering Camp Discovery

Bullous Diseases News & Research